UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  FORM 10-QSB

     (Mark  One)

     [ X ] Quarterly report under Section 13 or 15(d) of the Securities Exchange
     Act  of  1934

     For  the  quarterly  period  ended  March 31, 2002

     [    ]  Transition  report  under  Section  13  or  15(d) of the Securities
     Exchange  Act  of  1934

     For  the  transition  period  from  _________  to  _________

     Commission  File  No.  0-27039

                                 PROTEO, INC.
                 (Name of Small Business Issuer in Its Charter)

          NEVADA                                      88-0292249
(State or Other Jurisdiction of                     (IRS Employer
Incorporation or Organization)                 Identification Number)

                         2775 MESA VERDE EAST, F#101
                        COSTA MESA, CALIFORNIA, 92626
              (Address of Principal Executive Offices) (Zip Code)

                              (949) 979-7074
                       (Issuer's Telephone Number)

           SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
                                     (None)

           SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
                         Common Stock, par value $0.0001
                                (Title of Class)

     Check  whether  the  issuer  (1)  filed all reports required to be filed by
Section  13  or 15(d) of the Exchange Act during the past 12 months (or for such
shorter  period  that the registrant was required to file such reports); and (2)
has  been  subject  to  such  filing  requirements  for  the  past  90  days.

     Yes  [ X ]    No [   ]


     Indicate  the number of shares outstanding of each of the issuer's class of
common  stock  as  of  the  latest  practicable  date:

   Title of each class of Common Stock         Outstanding as April 30, 2002
   ----------------------------------------- ----------------------------------
   Common  Stock,  $0.0001  par  value                  20,414,444



     Transitional  Small  Business  Disclosure  Format  (check  one):

Yes [   ]  No [ X ]

<PAGE>

INDEX

                                PROTEO, INC.

PART  I.  FINANCIAL  INFORMATION

Item  1.  Consolidated  Financial  Statements

     Consolidated Balance Sheets at March 31, 2002 (Unaudited)

     Consolidated  Statements  of  Operations (Unaudited) for the three
     months  ended  March  31,  2002

     Consolidated Statements of Cash Flows (Unaudited) for the three months
     ended March  31,  2002

     Notes  to  Consolidated  Financial  Statements  (Unaudited)

Item 2.  Plan of Operations

PART  II.  OTHER  INFORMATION

Item  1.  Legal  Proceedings

Item  2.  Changes  in  Securities

Item  3.  Defaults  Upon  Senior  Securities

Item  4.  Submission  of  Matters  to  a  Vote  of  Security  Holders

Item  5.  Other  Information

Item  6.  Exhibits  and  Reports  on  Form  8-K

<PAGE>
ITEM  1.  FINANCIAL  STATEMENTS

<TABLE>
<CAPTION>


                                  PROTEO, INC.

                        BALANCE SHEET - MARCH 31, 2002
                                  (UNAUDITED)

<S>                                                                                     <C>
                                   ASSETS
 Current assets -
    cash                                                                                $      -
                                                                                         -------
                    LIABILITIES AND STOCKHOLDERS' EQUITY

 Current liabilities                                                                           -
 Stockholders' equity:
    Preferred stock; $0.001 par value, 10,000,000 shares authorized, no                 $      -
 shares issued and outstanding
    Common stock; $0.001 par value, 300,000,000 shares authorized, 1,308,594               1,308
 shares issued and outstanding
    Additional paid in capital                                                            (1,308)
    Accumulated deficit                                                                        -
                                                                                         -------
       Total stockholders' equity                                                              -
                                                                                         -------
                                                                                        $
                                                                                         -------

</TABLE>

See accompanying notes to unaudited financial statements.


<PAGE>
<TABLE>
<CAPTION>
                               PROTEO, INC.
                         STATEMENTS OF OPERATIONS


                                                      Three months ended
                                                            March 31,
                                                          (Unaudited)
                                                        2002       2001
                                                     ---------  ---------
<S>                                                  <C>        <C>
Revenues                                             $       -  $       -
 Cost of revenues                                            -          -
                                                     ---------  ---------
 Gross profit                                                -          -
                                                     ---------  ---------
 General and administrative expenses                         -     22,178
                                                     ---------  ---------
 Net loss                                            $       -    (22,178)
                                                     ---------  ---------
 Weighted average common equivalent shares           1,308,594  1,177,735
 outstanding -                                       ---------  ---------
 Net loss per share, basic and diluted               $       -   $  (0.02)
                                                     ---------  ---------
</TABLE>

See accompanying notes to unaudited financial statements.

<TABLE>
<CAPTION>

                                     PROTEO, INC.
                               STATEMENTS OF CASH FLOWS


                                                         Three months ended
                                                              March 31,


                                                          2002        2001
                                                       (Unaudited) (Unaudited)
<S>                                                    <C>          <C>
 Cash flows provided by (used for) operating
 activities:
    Net loss                                            $       -   $ (22,178)

 Adjustments to reconcile net lossincome to net cash
 provided by (used for) operating activities:
       Non-cash stock compensation                              -           -
 Changes in assets and liabilities:
    Increase (decrease) in liabilities -
       accrued expenses                                         -       2,407
                                                        ______________________
       Total adjustments                                        -       2,407

       Net cash used for operating activities                         (19,771)
                                                        _______________________
 Cash flows provided by financing activities -
    proceeds from private placement, net                        -           -
 Net increase (decrease ) in cash                                     (19,771)

Cash and equivalents, beginning of period                              245,534
                                                        _______________________
 Cash and equivalents, end of period                     $      -     $225,763
                                                        _______________________

</TABLE>

See accompanying notes to unaudited financial statements.






<PAGE>
                             PROTEO, INC.
                UNAUDITED NOTES TO FINANCIAL STATEMENTS
              THREE MONTHS ENDED MARCH 31, 2002 AND 2001

(1)     SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES:

Proteo,  Inc. (the "Company") was organized on December 18, 1992, under the laws
of  the  State  of Nevada as The Flintlock Company. On May 18, 1999, the name of
the  Company  was  changed  from  the  American  Flintlock Company to PageActive
Holdings,  Inc.  On  July  11,  2001,  the  name  of  the Company was changed to
TriVantage  Group,  Inc.  and  on  January 11, 2002, the name of the Company was
changed  to  Proteo,  Inc.

Sitestar  Applied  Technologies,  Inc.  ("SAT")  was  incorporated  in Nevada on
October 12, 2000. SAT is a wholly-owned subsidiary of Sitestar.net, Inc. ("SDN")
which  is  a wholly-owned subsidiary of Sitestar Corporation. Upon the formation
of  SAT,  SDN  contributed  all of the assets and liabilities of its development
division  to SAT in exchange for 100% of the issued and outstanding common stock
of  SAT.

MERGERS  AND  ACQUISITIONS:

On  July  11,  2001,  the  Company  completed  an  acquisition transaction  (the
"Acquisition") in accordance with a Plan of Reorganization and Acquisition dated
June  1,  2001,  with  SAT.  As  a  consequence of the Acquisition, SAT became a
wholly-owned  subsidiary  of  TriVantage Group, Inc. ("TriVantage") and Sitestar
Corporation,  the  parent  company  of  SDN  became  a  major shareholder owning
1,177,735  shares,  representing  approximately  90%  of  the  total  issued and
outstanding  common  stock  of TriVantage. The acquisition of SAT by the Company
has  been  accounted  for as a reverse merger.  Prior to the merger, the Company
had  no  business  activity  and therefore pro forma operating results as if the
acquisition  had taken place at the beginning of the periods presented, have not
been  presented.  For  accounting purposes, SAT has been treated as the acquirer
and  accordingly,  SAT is presented as the continuing entity, and the historical
financial  statements  are  those  of  SAT.

On  December  28,  2001,  SDN  repurchased  ("Repurchase") all of the assets and
liabilities  of SAT in exchange for the cancellation of the intercompany payable
due  to  SDN,  as of the date of the Repurchase. Also, on December 28, 2001, the
Company  entered  into  a  Shell  Acquisition  Agreement  (the  "Acquisition
Agreement")  with  Proteo,  Inc.,  a  Nevada  corporation  ("Old Proteo"), which
results  in a restructuring of the Company's management, Board of Directors, and
ownership.  In  accordance with the Acquisition Agreement, Proteo, Inc. acquired
1,177,735  shares  of the Company's common stock, representing approximately 90%
of  the  issued  and  outstanding  common  stock  of  the  Company.

<PAGE>
                             PROTEO, INC.
                UNAUDITED NOTES TO FINANCIAL STATEMENTS
              THREE MONTHS ENDED MARCH 31, 2002 AND 2001
                             (CONTINUED)

(1)     SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES,  CONTINUED:

MERGERS  AND  ACQUISITIONS,  CONTINUED:

Upon  completion  of  the  Acquisition  Agreement,  the  name of the Company was
changed  to  Proteo,  Inc.  Simultaneously  with  the  name  change, the Company
completed  a  one  for  one  hundred  fifty  reverse  stock  split of its equity
securities  (all  applicable  share  and  share  data  has been adjusted for the
reverse  stock  split).  Following completion of the reverse stock split and the
name  change,  the Company was to issue an aggregate of 20,286,512 shares to the
shareholders  of  Proteo  Marketing,  Inc., a wholly owned subsidiary of Proteo,
Inc.  in  consideration  for  their  Proteo  Marketing,  Inc. shares to effect a
reverse  acquisition between the Company and Proteo Marketing, Inc.  As of April
25,  2002,  the  reverse  acquisition with Proteo Marketing, Inc. was completed.

BASIS  OF  PRESENTATION:

The  accompanying  unaudited  interim  financial  statements  of  Proteo,  Inc.
("Company")  have  been  prepared  in  accordance  with  accounting  principles
generally  accepted  in  the  United  States  for interim financial information.
Accordingly,  they  do  not include all of the information and notes required by
accounting  principles  generally  accepted  in  the  United States for complete
financial  statements.  The  accompanying  financial  statements  reflect  all
adjustments (consisting of normal recurring accruals), which are, in the opinion
of  management,  considered necessary for a fair presentation of the results for
the interim periods presented. Operating results for the quarter ended March 31,
2002  are not necessarily indicative of the results that may be expected for the
fiscal  year ending December 31, 2002. These financial statements should be read
in  conjunction  with the audited financial statements included in the Company's
Annual  Report  on  Form10-KSB.

The  accompanying  financial  statements  have  been  prepared assuming that the
Company  will  continue  as  a  going  concern.  As  shown  in  the accompanying
financial statements, the Company has no operations.  Management intends to seek
a  merger  with  a  company  that  has  sustainable  operations.

USE  OF  ESTIMATES:

The preparation of financial statements in conformity with accounting principles
generally  accepted  in the United States of America requires management to make
estimates  and  assumptions  that  affect  the  reported  amounts  of assets and
liabilities  and disclosures of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenue and expenses during
the  reporting  periods.  Actual  results  could  differ  from  these estimates.

EXPENSE  ALLOCATIONS:

The Company is located and shares office space with its parent, Sitestar.net and
as  a result the two companies shares many of the general and administrative and
overhead  expense associated with operating the two companies.  Principally, the
allocation  of general and administrative and overhead expenses are allocated to
the  Company  based  upon a percentage of its revenue compared to the revenue of
its  parent.

INCOME  TAXES:

The  Company  accounts  for  income  taxes  in  accordance  with  SFAS  No. 109,
"Accounting  for  Income  Taxes".  Deferred  taxes  are  provided on a liability
method  whereby  deferred  tax  assets  are  recognized for deductible temporary
differences,  and  deferred tax liabilities are recognized for taxable temporary
differences.  Temporary  differences  are  the  differences between the reported
amounts  of assets and liabilities and their tax bases.  Deferred tax assets are
reduced  by a valuation allowance when, in the opinion of management, it is more
likely  than  not  that  some  portion or all of the deferred tax assets will be
realized.  Deferred  tax  assets and liabilities are adjusted for the effects of
changes  in  tax  laws  and  rates  on  the  date  of  enactment.


<PAGE>
                             PROTEO, INC.
                UNAUDITED NOTES TO FINANCIAL STATEMENTS
              THREE MONTHS ENDED MARCH 31, 2002 AND 2001
                             (CONTINUED)

(1)     SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES,  CONTINUED:

LOSS  PER  SHARE:

In  accordance  with  SFAS  No.  128,  "Earnings  Per Share", the basic loss per
common  share  is computed by dividing net loss available to common stockholders
by  the  weighted average number of common shares outstanding.  Diluted loss per
common  share is computed similar to basic loss per common share except that the
denominator  is increased to include the number of additional common shares that
would  have  been outstanding if the potential common shares had been issued and
if  the  additional common shares were dilutive.  The Company has no potentially
dilutive  securities.

COMPREHENSIVE  INCOME:

SFAS  No.  130,  "Reporting Comprehensive Income," establishes standards for the
reporting  and  display  of  comprehensive  income  and  its  components  in the
financial  statements.  As  of  December  31,  2001 and 2000, the Company has no
items that represent other comprehensive income and, therefore, has not included
a  schedule  of  comprehensive  income  in  the  financial  statements.

RECENTLY  ISSUED  ACCOUNTING  PRONOUNCEMENTS:

In  July  2001,  the FASB issued SFAS No. 141 "Business Combinations."  SFAS No.
141  supersedes Accounting Principles Board ("APB") No. 16 and requires that any
business  combinations  initiated  after  June  30,  2001  be accounted for as a
purchase;  therefore,  eliminating the pooling-of-interest method defined in APB
16.  The  statement  is  effective  for any business combination initiated after
June  30, 2001 and shall apply to all business combinations accounted for by the
purchase method for which the date of acquisition is July 1, 2001 or later.  The
Company  adopted  SFAS  No. 141 on July 1, 2001 and the adoption had no material
impact  on  the  Company's  financial  position  or  results  of  operations.

In  July  2001,  the FASB issued SFAS No. 142, "Goodwill and Other Intangibles."
SFAS  No. 142 addresses the initial recognition, measurement and amortization of
intangible assets acquired individually or with a group of other assets (but not
those  acquired  in  a  business  combination)  and  addresses  the amortization
provisions for excess cost over fair value of net assets acquired or intangibles
acquired  in a business combination. The statement is effective for fiscal years
beginning  after  December  15,  2001,  and  is  effective  July 1, 2001 for any
intangibles  acquired  in  a business combination initiated after June 30, 2001.
The  Company  adopted  SFAS  No.  141 on January 1, 2002 and the adoption had no
material  impact  on  the Company's financial position or results of operations.
The  Company  is  evaluating  any  accounting  effect,  if any, arising from the
recently  issued SFAS No. 142, "Goodwill and Other Intangibles" on the Company's
financial  position  or  results  of  operations.

<PAGE>
                             PROTEO, INC.
                UNAUDITED NOTES TO FINANCIAL STATEMENTS
              THREE MONTHS ENDED MARCH 31, 2002 AND 2001
                             (CONTINUED)

(1)     SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES,  CONTINUED:

RECENTLY  ISSUED  ACCOUNTING  PRONOUNCEMENTS,  CONTINUED:

In  October  2001,  the FASB recently issued SFAS No. 143, "Accounting for Asset
Retirement  Obligations," which requires companies to record the fair value of a
liability  for  asset  retirement  obligations  in  the period in which they are
incurred.  The  statement  applies  to  a company's legal obligations associated
with  the  retirement  of  a  tangible  long-lived  asset  that results from the
acquisition,  construction, and development or through the normal operation of a
long-lived  asset.  When  a  liability  is initially recorded, the company would
capitalize  the  cost,  thereby  increasing  the  carrying amount of the related
asset.  The  capitalized  asset  retirement cost is depreciated over the life of
the respective asset while the liability is accreted to its present value.  Upon
settlement of the liability, the obligation is settled at its recorded amount or
the  company  incurs a gain or loss. The statement is effective for fiscal years
beginning after June 30, 2002.  The Company does not expect the adoption to have
a  material impact to the Company's financial position or results of operations.

In October 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or
Disposal  of  Long-Lived  Assets".  Statement  144  addresses the accounting and
reporting  for  the  impairment  or disposal of long-lived assets. The statement
provides  a single accounting model for long-lived assets to be disposed of. New
criteria  must  be  met  to  classify  the asset as an asset held-for-sale. This
statement  also focuses on reporting the effects of a disposal of a segment of a
business.  This statement is effective for fiscal years beginning after December
15,  2001.  The Company adopted SFAS No. 141 on January 1, 2002 and the adoption
had  no  material  impact  on  the  Company's  financial  position or results of
operations.

(2) SUBSEQUENT EVENT

On  December  28,2001,  Proteo  Marketing, Inc. (which at that time was known as
"Proteo,  Inc.") acquired approximately 90% of the issued and outstanding shares
of  the  Company, Proteo, Inc. (which at the time was known as Trivantage Group,
Inc.).  Subsequent  to  the acquisition, the Company changed its name to Proteo,
Inc.  and  old Proteo changed its name to Proteo Marketing, Inc. ("Old Proteo").

On April 25, 2002, the Company and Old Proteo entered into an Agreement and Plan
of Share Exchange (the "Exchange Agreement") whereby the Company acquired all of
the outstanding shares of Old Proteo in exchange for 20,286,512 of the Company's
newly  issued  shares  of  common stock (the "Share Exchange"). As a result, Old
Proteo  became  a  wholly  owned  subsidiary  of  the  Company.

<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF  OPERATIONS

CAUTIONARY  STATEMENTS:

This Quarterly Report on Form 10-QSB contains certain forward-looking statements
within  the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of  the  Securities  Exchange  Act  of  1934.  The  Company  intends  that  such
forward-looking  statements  be  subject  to  the  safe  harbors created by such
statutes.  The  forward-looking  statements included herein are based on current
expectations  that  involve a number of risks and uncertainties. Accordingly, to
the  extent  that  this  Quarterly  Report  contains  forward-looking statements
regarding  the financial condition, operating results, business prospects or any
other  aspect  of  the  Company,  please  be  advised  that the Company's actual
financial  condition,  operating  results  and  business  performance may differ
materially  from  that  projected or estimated by the Company in forward-looking
statements. The differences may be caused by a variety of factors, including but
not  limited  to  adverse  economic  conditions,  intense competition, including
intensification  of price competition and entry of new competitors and products,
adverse  federal,  state  and  local  government regulation, inadequate capital,
unexpected  costs  and  operating  deficits,  and  increases  in  general  and
administrative  costs,  and  other specific risks that may be alluded to in this
Quarterly  Report  or  in  other reports issued by the Company. In addition, the
business  and  operations  of  the Company are subject to substantial risks that
increase  the  uncertainty  inherent  in  the  forward-looking  statements.  The
inclusion  of  forward looking statements in this Quarterly Report should not be
regarded  as  a  representation  by  the  Company  or  any other person that the
objectives  or  plans  of  the  Company  will  be  achieved.

The Company does not currently generate any revenue from its operations and does
not  expect to report any revenue until the successful development and marketing
of  its  planned pharmaceutical and other biotech products.  Additionally, after
the  launch of the Company's service, there can be no assurance that the Company
will  generate positive cash flow and there can be no assurances as to the level
of  revenues,  if  any,  the  Company  may  actually  achieve  from  its planned
operations.

Implementation Plan

The  Company intends to specialize in the research, development and marketing of
drugs  for inflammatory diseases with Elafin as its first project. The Company's
management  deems  Elafin  to  be  one of the most prospective substances in the
treatment  of  serious  tissue and muscle damage. Independently conducted animal
experiments  have  indicated  that  Elafin may have benefits in the treatment of
tissue  and muscle damage caused by insufficient oxygen supply and therefore may
be  useful in the treatment of heart attacks, serious injuries and in the course
of  organ  transplants.  Other  application  have  yet  to  be  determined.

The  Company  intends  to implement Elafin as a drug in the treatment of serious
tissue  and  muscle damage, e.g. due to traffic accidents and intends to achieve
governmental  approval  in  Europe first.  Currently, management assumes that it
will take at least five years to achieve first governmental approval for the use
of  Elafin  as  a drug in the treatment of serious tissue and muscle damage.  In
order  to  conduct  pre-clinical  and  clinical  trials,  the Company must first
complete  the  research  and  development  of an efficient production process in
accordance  with  GMP  (Good  Manufacturing  Practices)  standards.

The  Company's  success  will  depend  on  its  ability  to  implement efficient
production  process  in  accordance with GMP standards, to examine toxicology in
animal experiments, and to prove that Elafin is well tolerated by humans and its
efficiency  in  the  indicated  treatment.  There  can  be no assurance that the
Company  will  be  able  to develop feasible production procedures in accordance
with  GMP  standards,  or that Elafin will receive any governmental approval for
the  use  as  drug  in  any  of  the  intended  applications.

In  collaboration  with  a  non-affiliated  third party company, the Company has
identified  the yeast to be utilized in the production of Elafin and has ordered
the third party to develop efficient clones of such yeasts.  Simultaneously, the
Company  is  attempting  to  optimize  the  yeast expression systems to increase
efficient  production  of  such  yeasts.  Also, the Company is in the process of
equipping  its  recently  rented  facilities  and  to  scale up its fermentation
facilities  to  be able to produce sufficient amounts of Elafin for its research
and  development. The Company's management intends to have animal experiments on
the  toxicology  as  needed  to  enter governmental approval procedures in 2003.

LIQUIDITY  AND  CAPITAL  RESOURCES

Since  Inception,  the Company's wholly owned subsidiary, Proteo Marketing, Inc.
has raised a total of $1,500,000 from the sale of 500,000 shares of common stock
to  a German broker / dealer.  In addition, the Company sold 6,000,000 shares at
$0.40  per  share  to  the  same entity in exchange for a promissory note in the
amount  of  $2,400,000 bearing no interest.  As of March 31, 2002, the Company's
subsidiary  has  received  approximately  $212,000  from  the  note.

Additionally, the Company's wholly owned German subsidiary Proteo Biotech AG has
received  a  grant  from  the  German  state Schleswig-Holstein in the amount of
approximately  $700,000.  Such  grant  shall  cover  49.99% of related costs and
expenses  of research and development of the Company's Elafin project during the
period from 2001 to 2004 and will be offset against such costs and expenses. The
grant  will  depend  on  the Company's ability to cover 50.01% of such costs and
expenses,  and  from  the  achievement  of milestones. As of March 31, 2002, the
Company  has  received  $170,000  of  the  grant which have been set off against
related  expenses.

The  Company's  cash  was  approximately  $530,000  as  of  March  31, 2002. The
Company's management assumes that the Company will not have significant revenues
within the next years, and therefore the success and the business of the Company
will  depend  mainly on its ability to utilize other means of funding as sale of
stock,  public  funding  or  loans.  However, there can be no assurance that the
Company  will  be  able  to  raise  sufficient  funds  to  support  its  product
development  and  overall  business.

CAPITAL  EXPENDITURES

The  Company  intends  to  equip  its  rented  facilities to be eligible for the
Company's  research  and  development.  The costs are estimated at approximately
$350,000.


                                      PART II
                                  OTHER INFORMATION



Item 1.  Legal Proceedings

The  Company  may  from  time  to  time be involved in various claims, lawsuits,
disputes with third parties, actions involving allegations of discrimination, or
breach  of  contract  actions  incidental  to the operation of its business. The
Company is not currently involved in any such litigation which it believes could
have  a  materially  adverse  effect  on  its  financial condition or results of
operations.

Item 2.  Changes in Securities and Use of Proceeds

On  April  25,  2002,  pursuant  to an Agreement and Plan of Share Exchange, the
Company  issued  an  aggregate  of  20,286,512 shares of its common stock to the
shareholders  of  Proteo  Marketing, Inc. The shares were issued without general
solicitation  in  a  private  transaction  to  foreign  residents  pursuant  to
Regulation  S  of  the  Securities  Act  of  1933.

Item 3.  Defaults Upon Senior Securities

None.

Item 4.  Submission Of Matters To A Vote Of Security Holders

On  January  9,  the  majority  of  the Company's shareholder voted to amend the
Company's  Articles  of  Incorporation  and  to  change its name to Proteo, Inc.

Item 5.  Other Information

None.

Item 6.  Exhibits and Reports on Form 8-K

(a)          Exhibits

None

(b)          Reports  on  Form  8-K

On  February  15,  2002,  as  amended  on February 27, 2002, the Company filed a
Current  Report  on  form  8-K  reporting  a  change  in its auditors of record.

On  April 5, 2002, Company filed a Current Report on form 8-K reporting a change
in  its  auditors  of  record.

On  April 5, 2002, Company filed a Current Report on form 8-K reporting the
completion of its Share Exchange with Proteo Marketing, Inc.
The following documents are filed as part of this report:


<PAGE>
                          SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934. The
registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                              PROTEO, INC.

                              By /s/ Joerg Alte
                              ----------------------------------
                              Joerg Alte
                              Chief Executive Officer & Chief
                              Financial Officer

Dated: May 15, 2002